Art. -Nr.: HY-13688

Copy Link Print Information

PJ34 hydrochloride

37 Cited Publications

Kundenbewertung

Based on 37 publication(s) in Google Scholar

PJ34 hydrochloride is an inhibitor of PARP1/2 with IC₅₀ of 110 nM and 86 nM, respectively.

Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.

Reinheit: 99.81%
CAS. Nr.: 344458-15-7
Formel: C₁₇H₁₈ClN₃O₂
Molecular Weight:331.80

Speicherung:

4°C, sealed storage, away from moisture

* In solvent : -80°C, 1 year; -20°C, 6 months (sealed storage, away from moisture)

PJ34 hydrochloride Chemical Structure

CAS. Nr.: 344458-15-7

Größe

Preis

Verfügbarkeit

Menge

Amount: USD 0.00

* Bitte wählen Sie Menge, bevor Sie Artikel hinzufügen.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biologische Aktivität
- Beschreibung
- IC₅₀ & Target
- In Vitro
- In Vivo
Chemical Information
Publications (37)
Lösungsmittel & Löslichkeit
- In Vitro
- In Vivo
Protokoll
Reinheit & Dokumentation
Verweise
Help & FAQs
Classifications
Bioz

Biologische Aktivität

Beschreibung

PJ34 hydrochloride is an inhibitor of PARP1/2 with IC₅₀ of 110 nM and 86 nM, respectively.

IC₅₀ & Target^[1]

PARP

110 nM (IC₅₀)

PARP-2

86 nM (IC₅₀)

PARP-1

110 nM (IC₅₀)

Alle PARP Isoform-spezifische Produkte anzeigen :

In Vitro

PJ34 inhibits the PARP enzyme activity with an IC₅₀ of 110±1.9 nM. To compare the neuroprotective properties of other PARP inhibitors in PC12 cells, PJ34 is evaluated using by LDH assay. PJ34 treatment also significantly and concentration dependently attenuates cell death at a concentration ranging from 10^-7 to 10^-5 M^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

To compare the potency and efficacy with other PARP inhibitors, PJ34 is evaluated at the doses of 3.2 and 10 mg/kg, respectively. PJ34 at the dose of 3.2 mg/kg significantly reduces cortical damage by 33%; however, 10 mg/kg dosing shows reversed effect (17% reduction)^[1]. PJ34 (25 mg/kg) reduces the levels of TNF-α mRNA in ischemic animals by 70% and these values in treated mice do not differ from that of sham or naive animals. Treatment of ischemic mice with PJ34 reduces the level of E-selectin mRNA by 81% and that of ICAM-1 mRNA by 54%, compared to vehicle-treated ischemic mice^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Chemical Information

CAS. Nr. 344458-15-7
Appearance Solid
Molecular Weight 331.80
Formel C₁₇H₁₈ClN₃O₂
Color Light yellow to yellow
SMILES

O=C(NC(C=C1C2=C3C=CC=C2)=CC=C1NC3=O)CN(C)C.Cl
Versand

Room temperature in continental US; may vary elsewhere.
Speicherung

4°C, sealed storage, away from moisture

* In solvent : -80°C, 1 year; -20°C, 6 months (sealed storage, away from moisture)

Publications (37)

All Cell Proliferation/Viability AssayCell Imaging/StainingRT-PCRIFHistological Imaging/StainingWB

Sort by:

Journal Impact Factor

Nat Aging

Converting cell death into senescence by PARP1 inhibition improves recovery from acute oxidative injury. [Abstract]

2024 May 9. PMID: 38724734

PJ34 hydrochloride purchased from MedChemExpress. Usage Cited in: Nat Aging. 2024 May 9. [Abstract]

IMR-90 human fibroblasts were incubated with the indicated death inhibitor or vehicle for 2 h, followed by H₂O₂ treatment (1 mM). Cell survival was measured using an MTS assay 24 h after 1 h H₂O₂ treatment of cells. The results showed that PJ34 (10 µM; pretreated for 2 h before applying H₂O₂) protected cells from oxidative stress-induced death, while no rescue was observed for other death inhibitors such as QVD (apoptosis), necrosulfonamide (necroptosis), ferrostatin-1 (ferroptosis), VX-765 (pyroptosis), pepstatin A (cathepsin D and E-induced death) and E64d (cathepsin B and L-induced, and calpain-induced death).

PJ34 hydrochloride purchased from MedChemExpress. Usage Cited in: Nat Aging. 2024 May 9. [Abstract]

IMR-90 human fibroblasts were incubated with the indicated death inhibitor or vehicle for 2 h, followed by H₂O₂ treatment (1 mM). Cells were stained for PAR polymers after 15 min H₂O₂ exposure; n = 152 from three independent experiments. Quantification was performed on single cells with images taken from multiple microscopic fields of view. The results showed that cells exposed toH₂O₂ showed a strong nuclear poly-ADP-ribose (PAR) signal that was significantly suppressed by PJ34 (10 µM; pretreated for 2 h before applying H₂O₂), indicating an on-target effect of the inhibitor. Scale bar, 150 µm.

PJ34 hydrochloride purchased from MedChemExpress. Usage Cited in: Nat Aging. 2024 May 9. [Abstract]

IMR-90 human fibroblasts were incubated with the indicated death inhibitor (PJ34 (10 µM)) or vehicle for 2 h, followed by H₂O₂ treatment (1 mM). Fourteen days after treatment cells were analyzed using quantitative PCR with reverse transcription (RT–qPCR) for expression of the indicated mRNAs relative to the housekeeping gene (tubulin); n = 6.

PJ34 hydrochloride purchased from MedChemExpress. Usage Cited in: Nat Aging. 2024 May 9. [Abstract]

Immunofluorescence staining with TOM20 and endogenous HK-II of IMR-90 cells pretreated with vehicle or PJ34 exposed to H₂O₂ (1 mM); control, n = 94, H₂O₂ and H₂O₂ + PJ34 (10 µM; pretreated for 2 h before applying H₂O₂), n = 87 from three independent experiments, Scale bar, 10 µm. The results showed that incubation with PJ34 in cells exposed to H₂O₂ was sufficient to retain the mitochondrial pool of HK-II.

PJ34 hydrochloride purchased from MedChemExpress. Usage Cited in: Nat Aging. 2024 May 9. [Abstract]

Mice underwent unilateral kidney IRI with the administration of the PARP inhibitor PJ34 (10 mg/kg) or vehicle. Three days after induction of IRI, kidney tissues were collected for histological and molecular analysis. Periodic acid–Schiff staining was used to detect the necrotic area (defined by a red line), n = 5 for vehicle-treated and n = 6 for PJ34-treated mice. Scale bar, 100 µm. The results showed that IRI was characterized by an increased necrotic area, which was considerably reduced by PJ34 treatment.
Autophagy

METTL3-dependent m6A modification of SNAP29 induces "autophagy-mitochondrial crisis" in the ischemic microenvironment after soft tissue transplantation. [Abstract]

2025 Oct;21(10):2168-2191. PMID: 40340690
Sci Adv

PARP1 stabilizes FOXN3 to suppress pulmonary fibrosis through p38-related feedback regulation. [Abstract]

2026 Jan 2;12(1):eady1681. PMID: 41481720
Cell Death Dis

IFI16 is essential to linking DNA damage and ferroptosis in acute kidney injury. [Abstract]

2026 Mar 23;17(1):350. PMID: 41872158
Cancer Lett

NCAPD2 inhibits autophagy by regulating Ca2+/CAMKK2/AMPK/mTORC1 pathway and PARP-1/SIRT1 axis to promote colorectal cancer. [Abstract]

2021 Nov 1:520:26-37. PMID: 34229059
Phytomedicine

Echinacoside modulates PARP14-GLUD1 axis to mediate energy metabolism reprogramming and mitochondrial function in diminished ovarian reserve. [Abstract]

2026 Jun:155:158100. PMID: 41895093
Part Fibre Toxicol

Silica nanoparticles induce lung inflammation in mice via ROS/PARP/TRPM2 signaling-mediated lysosome impairment and autophagy dysfunction. [Abstract]

2020 Jun 8;17(1):23. PMID: 32513195
Acta Biomater

An auto-photoacoustic melanin-based drug delivery nano-platform for self-monitoring of acute kidney injury therapy via a triple-collaborative strategy. [Abstract]

2022 Jul 15:147:327-341. PMID: 35643195
J Transl Med

YY1 drives PARP1 expression essential for PARylation of NONO in mRNA maturation during neuroblastoma progression. [Abstract]

2024 Dec 27;22(1):1153. PMID: 39731187
Proc Natl Acad Sci U S A

Muscle PARP1 inhibition extends lifespan through AMPKα PARylation and activation in Drosophila. [Abstract]

2023 Mar 28;120(13):e2213857120. PMID: 36947517
Apoptosis

Poly(ADP-ribose) polymerase inhibitor PJ34 protects against UVA-induced oxidative damage in corneal endothelium. [Abstract]

2021 Dec;26(11-12):600-611. PMID: 34581992
Antioxidants (Basel)

Luteolin Alleviates Cadmium-Induced Kidney Injury by Inhibiting Oxidative DNA Damage and Repairing Autophagic Flux Blockade in Chickens. [Abstract]

2024 Apr 26;13(5):525. PMID: 38790630
Free Radic Biol Med

Hydroxysafflor yellow A and anhydrosafflor yellow B alleviate ferroptosis and parthanatos in PC12 cells injured by OGD/R. [Abstract]

2022 Feb 1:179:1-10. PMID: 34923102
J Invest Dermatol

TRPV3-Activated PARP1/AIFM1/MIF Axis through Oxidative Stress Contributes to Atopic Dermatitis. [Abstract]

2024 May 30:S0022-202X(24)00384-1. PMID: 38823435
Sci Signal

Tyrosine kinase inhibitors can activate the NLRP3 inflammasome in myeloid cells through lysosomal damage and cell lysis. [Abstract]

2023 Jan 17;16(768):eabh1083. PMID: 36649377
Cell Mol Life Sci

LncRNA ENST00000532153.1 alleviates podocyte injury by inhibiting PARP1-mediated PARylation of ATF3 in diabetic kidney disease. [Abstract]

2025 Oct 25;82(1):363. PMID: 41137902
Drug Des Devel Ther

PJ34 Prevents Trauma-Induced Heterotopic Ossification without Adverse Bone Healing: An in vivo and in vitro Investigation. [Abstract]

2026 Mar 23:20:561571. PMID: 41908940
J Enzyme Inhib Med Chem

Natural product sennoside B disrupts liquid-liquid phase separation of SARS-CoV-2 nucleocapsid protein by inhibiting its RNA-binding activity. [Abstract]

2025 Dec;40(1):2501743. PMID: 40371698
Bioorg Chem

Identification of FTY720 and COH29 as novel topoisomerase I catalytic inhibitors by experimental and computational studies. [Abstract]

2024 Jun:147:107412. PMID: 38696845
Biochim Biophys Acta Mol Basis Dis

MTH1 inhibition synergizes with ROS-inducing agents to trigger cervical cancer cells undergoing parthanatos. [Abstract]

2024 Apr 22;1870(5):167190. PMID: 38657912
Mol Med Rep

Network pharmacology combined with experimental validation to investigate the effect of Rongjin Niantong Fang on chondrocyte apoptosis in knee osteoarthritis. [Abstract]

2024 Jun;29(6):102. PMID: 38639187
J Mol Med (Berl)

Combination of PARP inhibitor and temozolomide to suppress chordoma progression. [Abstract]

2019 Aug;97(8):1183-1193. PMID: 31201471
Sci Rep

NAD+ loss, a new player in AhR biology: prevention of thymus atrophy and hepatosteatosis by NAD+ repletion. [Abstract]

2017 May 23;7(1):2268. PMID: 28536482

PJ34 hydrochloride purchased from MedChemExpress. Usage Cited in: Sci Rep. 2017 May 23;7(1):2268. [Abstract]

The PARP inhibitor PJ34 prevents TCDD toxicities while increasing NAD⁺ levels. (a,b) Western blots on homogenates of liver and thymus glands from CE treated with TCDD or vehicle with or without PJ34.
Exp Neurol

PARP1 modulates BBB function via regulating NLRC5 in cerebral endothelial cells during ischemic stroke. [Abstract]

2026 Oct:404:115862. PMID: 42235665
Neurochem Res

β-Lapachone-Induced Oxidative Stress Causes PARP-Dependent NAD+-Depletion that Affects the Energy Metabolism of Cultured Primary Rat Astrocytes. [Abstract]

2026 Jun 12;51(3):192. PMID: 42277481
Microbiol Spectr

Cell type-dependent induction of type I interferon and PARP1 activation in astrocytes and neurons during chikungunya virus infection. [Abstract]

2026 Jun 24:e0417825. PMID: 42370697
J Virol

Inhibition of PARP1 Dampens Pseudorabies Virus Infection through DNA Damage-Induced Antiviral Innate Immunity. [Abstract]

2021 Jul 26;95(16):e0076021. PMID: 34037418
Regen Ther

Non-apoptotic regulated cell death in Fuchs endothelial corneal dystrophy. [Abstract]

2023 Nov 10:24:592-601. PMID: 38034859
Anim Cells Syst

Restoration of NAD+ homeostasis protects C2C12 myoblasts and mouse levator ani muscle from mechanical stress-induced damage. [Abstract]

2022 Aug 3;26(4):192-202. PMID: 36046029
Norges teknisk-naturvitenskapelige universitet

2025.
bioRxiv

2025 March 26.
Norges teknisk-naturvitenskapelige universitet

2024.
bioRxiv

Global remodeling of ADP-ribosylation by PARP1 suppresses influenza A virus infection. [Abstract]

2024 Sep 19:2024.09.19.613696. PMID: 39345583
bioRxiv

2023 Oct 4.
Nottingham Trent University

2023 Sep 12.
Research Square Print

2022.
Patent

US20180263995A1.

Lösungsmittel & Löslichkeit

In Vitro:

H₂O : 50 mg/mL (150.69 mM; Need ultrasonic)

DMSO : 10 mg/mL (30.14 mM; ultrasonic and warming and heat to 60°C; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

3.0139 mL

15.0693 mL

30.1386 mL

5 mM

0.6028 mL

3.0139 mL

6.0277 mL

10 mM

0.3014 mL

1.5069 mL

3.0139 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 1 year; -20°C, 6 months (sealed storage, away from moisture). When stored at -80°C, please use it within 1 year. When stored at -20°C, please use it within 6 months.

* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.

Molaritätsrechner

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Konzentration Konzentration

Volumen Volumen

Molecular Weight Molecular Weight

Verdünnungsrechner

Konzentration _{(Stammlösung)} × Volumen _{(Stammlösung)} = Konzentration _{(Ziellösung)} × Volumen _{(Ziellösung)}

Konzentration _{(Stammlösung)} Konzentration _{(Stammlösung)}

Volumen _{(Stammlösung)} Volumen _{(Stammlösung)}

Konzentration _{(Ziellösung)} Konzentration _{(Ziellösung)}

Volumen _{(Ziellösung)} Volumen _{(Ziellösung)}

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 1 mg/mL (3.01 mM); Clear solution

This protocol yields a clear solution of ≥ 1 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (10.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)

Solubility: ≥ 1 mg/mL (3.01 mM); Clear solution

This protocol yields a clear solution of ≥ 1 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (10.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 1 mg/mL (3.01 mM); Clear solution

This protocol yields a clear solution of ≥ 1 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (10.0 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Working solution concentration: 0.22 mg/mL

This product has good water solubility, please refer to the measured solubility data in water/PBS/Saline for details.

The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only.If necessary, please contact

MedChemExpress (MCE) .

Protokoll

Kinase Assay^[1]

To assess the PARP-1 or PARP-2 inhibitory activity of FR247304, 3-AB, and PJ34, PARP activity is evaluated with minor modifications. PARP enzyme assay is carried out in a final volume of 100 μL consisting of 50 mM Tris-HCl (pH 8.0), 25 mM MgCl₂, 1 mM dithiothreitol, 10 μg activated salmon sperm DNA, 0.1 μCi of [adenylate-³²P]NAD, 0.2 units of recombinant human PARP for PARP-1 assay or 0.1 units of recombinant mouse PARP-2 for PARP-2 assay, and various concentrations of FR261529 or 3-AB. The reaction mixture is incubated at room temperature (23°C) for 15 min, and the reaction is terminated by adding 200 μL of ice-cold 20% trichloroacetic acid (TCA) and incubated at 4°C for 10 min. The precipitate is transferred onto GF/B filter and washed three times with 10% TCA solution and 70% ethanol. After the filter is dried, the radioactivity is determined by liquid scintillation counting.

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Assay^[1]

PC12 cell cultured are grown in Dulbecco's modified Eagle's medium supplemented with 5% (v/v) fetal calf serum, 5% (v/v) horse serum, and a 1% (v/v) penicillin-streptomycin antibiotics mixture. Cells are grown in an atmosphere of 95% air and 5% CO₂ at 37°C. For all experiment, cells are seeded at a density of 4×10⁴ cells/well in 96-well culture plates and allowed to attach overnight. For assessment of cell viability, hydrogen peroxide-induced cytotoxicity is quantified by a standard measurement of LDH release with the use of the LDH assay kit. Briefly, 6 h after hydrogen peroxide exposure, 20 μL of medium of each well is collected, and the solution prepared from LDH assay kit is added. After incubation at room temperature for 30 min, the reaction is stopped by addition of 1 N HCl, and absorbance is measured at 450 nm using a microplate reader.

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Administration^[1]^[2]

Rats^[1]
For transient focal ischemia, 9- to 10-week-old male Wistar rats (weighing 274-380 g) are used. FR247304, PJ34, or 3-AB, which is suspended with 0.5% methylcellulose, is administered at doses of 10 and 32 mg/kg for FR247304, 3.2 and 10 mg/kg for PJ34, or 32 and 100 mg/kg for 3-AB intraperitonially twice at 10 min before MCA occlusion and 10 min before recirculation. The administration volume is adjusted to 2 mL/kg.
Mice^[2]
Male Swiss albino mice (27-32 g) are used. The PARP inhibitor, PJ34 (1.25, 12.5 or 25 mg/kg) is dissolved in isotonic saline (NaCl, 0.9%) and injected intraperitoneally, in a volume of 10 mL/kg, 15 min before ischemia and again 4 h after the onset of ischemia. Control ischemic mice and sham animals are given vehicle (saline). Naive animals are also included in the studies.

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Reinheit & Dokumentation

Select Batch:

Reinheit: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (283 KB)
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

Verweise

[1]. Iwashita A, et al. A novel and potent poly(ADP-ribose) polymerase-1 inhibitor, FR247304 (5-chloro-2-[3-(4-phenyl-3,6-dihydro-1(2H)-pyridinyl)propyl]-4(3H)-quinazolinone), attenuates neuronal damage in in vitro and in vivo models of cerebral ischemia. J Ph [Content Brief]

[2]. Haddad M, et al. Anti-inflammatory effects of PJ34, a poly(ADP-ribose) polymerase inhibitor, in transient focal cerebral ischemia in mice. Br J Pharmacol. 2006 Sep;149(1):23-30. [Content Brief]

[3]. Diani-Moore S, et al. NAD+ loss, a new player in AhR biology: prevention of thymus atrophy and hepatosteatosis by NAD+ repletion. Sci Rep. 2017 May 23;7(1):2268. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO / H₂O	1 mM	3.0139 mL	15.0693 mL	30.1386 mL	75.3466 mL
	5 mM	0.6028 mL	3.0139 mL	6.0277 mL	15.0693 mL
	10 mM	0.3014 mL	1.5069 mL	3.0139 mL	7.5347 mL
	15 mM	0.2009 mL	1.0046 mL	2.0092 mL	5.0231 mL
	20 mM	0.1507 mL	0.7535 mL	1.5069 mL	3.7673 mL
	25 mM	0.1206 mL	0.6028 mL	1.2055 mL	3.0139 mL
	30 mM	0.1005 mL	0.5023 mL	1.0046 mL	2.5116 mL
H₂O	40 mM	0.0753 mL	0.3767 mL	0.7535 mL	1.8837 mL
	50 mM	0.0603 mL	0.3014 mL	0.6028 mL	1.5069 mL
	60 mM	0.0502 mL	0.2512 mL	0.5023 mL	1.2558 mL
	80 mM	0.0377 mL	0.1884 mL	0.3767 mL	0.9418 mL
	100 mM	0.0301 mL	0.1507 mL	0.3014 mL	0.7535 mL

* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.

Keywords

PJ34 hydrochloride

37 Cited Publications

100 mg Angebot einholen

Subscribe to the

MedChemExpress

Newsletter

Produktname:
Art. -Nr.:
Menge:
MCE Japan Authorized Agent:

Produktname:
CAS. Nr.:
Species:
Reinheit:
Menge:

PJ34 hydrochloride

Cell Cycle/DNA Damage Compound Library

Epigenetics Compound Library

Anti-Cancer Compound Library

Anti-Aging Compound Library

Neuroprotective Compound Library

Anti-Breast Cancer Compound Library

Anti-Pancreatic Cancer Compound Library

Targeted Diversity Library

Human Metabolite Library

Anti-Ovarian Cancer Compound Library

Multi-Target Compound Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Bioactive Compound Library

High-Throughput Bioactive Compound Library

Mass Spectrometry Human Metabolite Library

Publications Citing Use of MedChemExpress (MCE) PJ34 hydrochloride

Alle PARP Isoform-spezifische Produkte anzeigen

Biologische Aktivität

Chemical Information

Publications (37)

Lösungsmittel & Löslichkeit

Protokoll

Reinheit & Dokumentation

Verweise

Help & FAQs

Complete Stock Solution Preparation Table

PJ34 hydrochloride

Cell Cycle/DNA Damage Compound Library

Epigenetics Compound Library

Anti-Cancer Compound Library

Anti-Aging Compound Library

Neuroprotective Compound Library

Anti-Breast Cancer Compound Library

Anti-Pancreatic Cancer Compound Library

Targeted Diversity Library

Human Metabolite Library

Anti-Ovarian Cancer Compound Library

Multi-Target Compound Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Bioactive Compound Library

High-Throughput Bioactive Compound Library

Mass Spectrometry Human Metabolite Library

Publications Citing Use of MedChemExpress (MCE) PJ34 hydrochloride

Alle PARP Isoform-spezifische Produkte anzeigen

Biologische Aktivität

Chemical Information

Publications (37)

Lösungsmittel & Löslichkeit

Protokoll

Reinheit & Dokumentation

Verweise

Help & FAQs

Complete Stock Solution Preparation Table

PJ34 hydrochloride Related Classifications

HY-13688 Related Classifications